Introduction
New Delhi metallo-beta-lactamase 1 (NDM-1) is a newly-described metallo-beta-lactamase (MBL), first identified in 2008 in single isolates of Klebsiella pneumoniae and Escherichia coli, both recovered from a patient repatriated to Sweden after treatment in a hospital in New Delhi, India [1] . Like other acquired MBLs, NDM-1 hydrolyses all beta-lactam antibiotics except for aztreonam, which is usually inactivated by co-produced extended-spectrum or AmpC beta-lactamases. An association with other resistance mechanisms makes a majority of Enterobacteriaceae with bla NDM-1 extensively resistant to antibiotics and susceptible only to colistin and, less consistently, tigecycline [1, 2] .
Acquired carbapenemases are a large group of betalactamases of high structural diversity that, in most instances, hydrolyse not only carbapenems, but also oxyimino-cephalosporins and cephamycins [3] . For over a decade, different types of acquired carbapenemases have gradually begun to appear in clinical isolates of Enterobacteriaceae and other Gram-negative bacteria. In Europe, VIM-type MBLs and the socalled K. pneumoniae carbapenemases (KPC) are the most frequently isolated carbapenemases, although K. pneumoniae producing the class D OXA-48 carbapenemase is prevalent in Turkey ( [3, 4] . Overall, carbapenem-resistant Enterobacteriaceae are still rare causes of human infections in most parts of Europe, except for Greece and Cyprus [3] [4] [5] . According to the 2009 data from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS) [5] the rates of carbapenem-resistance among invasive K. pneumoniae infections were: 43.5% in Greece, 17 .0% in Cyprus, 1.3% in Italy, 1.2% in Belgium and below 1% in the other 23 reporting countries [5] . Despite these generally low rates, carbapenemase-producing strains of K. pneumoniae harbouring either bla VIM or bla KPC have been the cause of country-wide epidemics of healthcare-associated infections in Greece, Israel, the United States (US), several Latin American countries and China, and of local outbreaks in Poland and Italy [3, 4, 6] . These epidemic strains, plasmids, and transposons bearing carbapenemases have been shown to spread when carried by patients who are transferred between hospitals [3, 6] . Such introductions into healthcare systems across country borders have led to international epidemics by secondary local or regional transmission [1] [2] [3] 6] .
After the initial report of NDM-1 from Sweden in 2008 [1] , the Health Protection Agency (HPA) in the United Kingdom (UK), concerned over the rapid increase in the number of cases of human colonisation and infection with NDM-1 and other carbapenemase-producing Enterobacteriaceae in hospitals across the country, issued a national alert in July 2009 [7] . Similarly to the first case of NDM-1 reported by Yong et al. [1] , the majority of the patients with NDM-1-positive bacteria in the UK had a history of travel to India or Pakistan, where many of them had been hospitalised with various indications, including elective surgery and renal dialysis [2, 7] .
These reports indicate that the majority of the bacteria carry bla NDM-1 on conjugative plasmids of variable size [1, 2] . Among Enterobacteriaceae, E. coli and K. pneumoniae are the most frequent host species but NDM-1 has already been recorded in Klebsiella oxytoca, Citrobacter freundii, Enterobacter cloacae, Morganella morganii, Proteus spp. and Providencia spp. [1, 2] .
The worldwide spread of Enterobacteriaceae that carry carbapenemase-producing genes, including bla NDM-1 , is a significant threat to human health: Firstly, the production of carbapenemase, in association with other resistance determinants, confers extensive drug resistance, leaving few or no therapeutic options. Secondly, the association with travel underscores the risk of healthcare in countries where antibiotic-resistant bacteria are endemic [2] . Lastly, studies of patients infected with Enterobacteriaceae producing KPC are at increased risk of complications and death [8, 9] .
On 23 August 2010, following publication of the UK cases [2] , the French National Public Health Surveillance Institute (InVS) posted an alert on the European Early Warning and Response System (EWRS), to share with other European Union (EU) Member States information on two cases infected with NDM-1-producing bacteria related to hospitalisation on the Indian subcontinent. On 27 August, the European Centre for Disease Prevention and Control (ECDC) produced and shared with the Commission and all EU Member States a threat assessment on "New Delhi metallo-beta-lactamase (NDM-1) carbapenemase-producing Enterobacteriaceae from the Indian subcontinent", based on a preliminary review of all NDM-1-producing bacteria reported at that time in six EU member states (Belgium, France, Germany, the Netherlands, Sweden and the UK). The present study is an update of this initial assessment and describes the geographical distribution and epidemiological features of NDM-1-producing bacteria detected to date in the EU Member States, Iceland and Norway. It also reports on the availability of national guidance on detection, surveillance, notification and control of NDM-1-and other carbapenemase-producing Enterobacteriaceae in these countries.
Methods
We searched the medical literature for articles on "New Delhi metallo-beta-lactamase" OR "NDM-1" published until 15 November 2010 to identify cases reported from Europe and also included relevant references provided by consulted experts. To expand this search beyond published cases, an electronic questionnaire survey was sent out on 20 September 2010 to the ECDC National Antimicrobial Resistance Focal Points and the European Antimicrobial Resistance Surveillance Network (EARS-Net) Contact Points from all EU Member States, Iceland and Norway. The purpose of this survey was to register, by country, all cases of infection with NDM-1-producing bacteria. An NDM-1 case was defined as a patient from whom one or more Enterobacteriaceae had been isolated that expressed the NDM-1 enzyme as confirmed by an expert laboratory. The survey also collected the following clinical and microbiological data: the bacterial species producing the NDM-1 enzyme and the date of detection, the type of infection, the sex and age of the patient, the patient's clinical status at hospital discharge or at the last follow-up, any recent travel history (within the 30 days before detection of NDM-1) or contact with healthcare facilities abroad (also stating in which country), and any local transmission events with known contact with a travel-associated case.
The questionnaire also included queries about whether there were published national guidelines, recommendations or guidance documents addressing the following issues in the context of carbapenemase-producing Enterobacteriaceae: methods of microbiological detection, referral of isolates to reference microbiology laboratories, notification of public health authorities, and infection control measures to limit spread.
Results
We identified 19 peer-reviewed publications on NDM-1 enzyme [1,2,10-26], of which 12 reported primary data. NDM-1 cases reported from Europe (n=38) included two cases from Austria [20] , two from Belgium [25] , one from Denmark [23] , one from France [26] , two from the Netherlands [16, 24] , one from Sweden [1] and 29 from the UK [2] . Cases were also reported from Australia [18] , Canada [19] , Singapore [21] and the US [10] . Infections with NDM-1-producing Acinetobacter baumannii were reported from Germany, India and the UK [2, 17, 22] . Investigations showed that the NDM-1 enzyme was frequently detected among clinical Enterobacteriaceae isolates in Chennai, Haryana, Mumbai and other Indian cities [2, 10] .
All 29 questionnaires mailed to the countries were completed and returned. Table 1 Of the 77 cases reported in the questionnaires, 51 originated from the UK. The patients' age ranged from 2 to 87 years and the male:female ratio was 0.62.
Species information was available for 57 isolates (from 53 patients) producing an NDM-1 enzyme. They were distributed among six species:
morganii (n=2) and Proteus mirabilis (n=1).
In addition, the UK and Germany have recorded NDM-1 enzyme in Acinetobacter spp. (Table 1) .
Among the 26 cases reported in European countries other than the UK, 14 were thought to be colonised with NDM-1-enzyme-producing organisms, whereas 12 presented with infections affecting the urinary tract (n=6), skin and soft tissues (n=3), intra-abdominal cavity (n=2), and lung (n=1). Among all 77 cases reported, including from the UK, four patients developed a bloodstream infection. Seven of the 77 patients died in hospital: In a 51-year old diabetic patient, death was attributed to septic shock from a necrotic leg wound infected with an NDM-1-positive E. coli. In another case the fatal outcome was unrelated to NDM-1. For the remaining five fatal cases, information on the cause of death was not available.
Thirty-eight of the 55 cases with a travel history had a link either to the Indian subcontinent (n=33) or to the Balkan region (n=5). Different temporal criteria were applied to travel history by the UK and the other survey participants to define this link. Among the 29 cases in the UK, 17 had travelled to India or Pakistan in the year before detection of NDM-1. Among the 26 cases from other EU countries, 22 had travelled in the month before diagnosis to a foreign country: 13 to India, three to Pakistan, two to Kosovo, two to Serbia, one to Montenegro and one to Bosnia and Herzegovina (Table 1) .
Most patients with recent travel had been hospitalised in a foreign country during the 30 days prior to the detection of NDM-1 (Table 1 ). In the UK, 14 of 29 patients had been admitted within the three years before detection of NDM-1 to a foreign hospital in India (n=8), Pakistan (n=4), India and Dubai (n=1) and Spain (n=1). In the other reporting countries, 18 of 26 patients been admitted in the month before detection to a foreign hospital in India (n=10), the Balkans (n=5) or Pakistan (n=3) ( Table 1 ). It appears that the majority of these cases were admitted to foreign hospitals due to an illness or accident that occurred during the journey, although a minority were travelling for medical tourism.
Preliminary evidence suggests that 13 of 77 patients from Italy and the UK were possible secondary cases linked to other hospitalised patients who had returned from India (Table 1 ). In Italy, two cases with no travel history had stayed in a hospital unit to which a patient returning from India had previously been admitted. In the UK, 11 patients were involved in three clusters of possible cross-transmission. The hospital stay of two UK patients with no link to foreign countries overlapped with a travel-associated case. In another UK hospital, an endoscope-related outbreak affected nine patients six month after a travel-associated case.
National guidance was available in 14 European countries in the form of online or peer-reviewed publications, addressing the management of Enterobacteriaceae producing NDM-1 or other carbapenemases (Table 2) . They all recommended clinical laboratory methods for resistance detection and required that the resistance gene is confirmed by a reference laboratory. Cyprus and Latvia reported that reference microbiological methods were under development. It is of note that NDM-1 cases were reported in 10 of 14 countries with laboratory detection guidance, compared with three of 15 countries without such guidance (Tables 1 and 2 ). The majority of guidance documents also outlined the procedure for notification of health authorities and recommended infection control measures in healthcare facilities. Eight countries had a full set of guidance documents. Estonia, Ireland, and Slovakia indicated that such guidance was in development.
Guidance on control measures for patients with carbapenemase-producing Enterobacteriaceae was frequently part of broader recommendations on multidrug-resistant microorganisms. Finland stated that such guidance was under development in their country. Austria and Denmark indicated that infection control guidelines were developed by public health professionals at regional or hospital level. In France, guidance on the screening of patients transferred directly from foreign healthcare facilities was under revision to be extended to all patients exposed to such care facilities in the year preceding admission to a French hospital.
Discussion

Incidence and geographical distribution
Current data indicates an increase in the spread not only of NDM-1, but also of other carbapenemase-producing Enterobacteriaceae in Europe and worldwide [2] [3] [4] [5] [6] . We found here 77 NDM-1 cases in 13 countries in Europe over the last three years, with the majority of cases in the UK. It is likely that the number of cases reported is underestimated, because, in most countries, infections with highly-resistant Enterobacteriaceae are not notifiable, nor do they have to be laboratory-confirmed. Moreover, microbiological guidance on the detection and identification of acquired carbapenemases in Enterobacteriaceae is available in only a minority of European countries. These countries were more likely to identify cases. Cases have also been reported in 2010 from Australia [18] , Canada [19] , Singapore [21] , the US [10] , and, according to recent media reports, from China, Israel, Japan, Kenya, Malaysia, Oman and Taiwan. The majority of cases described in our survey, as in other reports, had a history of recent travel and hospital admission on the Indian subcontinent, but there was also a smaller proportion of cases who had received hospital care in Balkan countries. Further studies should determine the risk of healthcare-associated acquisition of NDM-1 and other carbapenemase-producing Enterobacteriaceae in different parts of the world.
Laboratory detection and identification
Carbapenem resistance mediated by NDM-1 enzyme has been detected by clinical laboratories with routine phenotypic testing methods, including disc diffusion testing [1, 2, 10, 11, [18] [19] [20] [21] [22] [23] [24] [25] [26] . Any Enterobacteriaceae isolate that exhibits a minimum inhibitory concentration (MIC) above the epidemiological cut-off or with clinical resistance to ertapenem, imipenem or meropenem should trigger further testing [12, 27] Carbapenemase activity can be screened by using the modified Hodge test [2, [10] [11] [12] and, as with other metallo-beta-lactamases, synergy can be detected by EDTA-imipenem disc or Etest [1,2,10-12,] . Widely used automated susceptibility systems show good sensitivity but poor specificity for detection of carbapenem resistance mediated by NDM-1 and other carbapenemases [13] . Further evaluation of in-house and commercial test systems with larger numbers of NDM-1-producing strains are desirable, given the variable phenotypic expression of carbapenemase activity, as observed with strains producing KPC-and VIM-like enzymes [3, 6, 11, 14, 15, 27] .
Confirmation of the NDM-1 enzyme requires molecular analysis, typically PCR or DNA sequencing, by a reference laboratory [1, 2, 7, 11] . A limitation of our study was the absence of a molecular case definition or a description of molecular NDM-1 identification methods. However, 38 of 77 cases described here have been published elsewhere with details of molecular identification (Table 1 ) and the majority of the remainder were reported by the same expert laboratories according to published national standards (Table 2) .
Epidemic risk assessment
What is the epidemic potential of NDM-1? The bla NDM-1 determinant was located on conjugative plasmids in the majority of the producer E. coli and K. pneumoniae clinical isolates [2] . In a few isolates, bla NDM-1 was located on the bacterial chromosome, indicating intragenomic recombination [2] . NDM-1 was produced both by a K. pneumoniae isolate from urine and a faecal E. coli isolate from the same patient, suggesting in vivo transfer [1] . These characteristics indicate a potent capacity for horizontal dissemination, as further evidenced by detection of bla NDM-1 in multiple genera of Enterobacteriaceae and in A. baumannii [2, 11] .
Many NDM-1 cases had co-morbidities and/or had undergone an invasive care procedure [1, 2, [19] [20] [21] [22] [23] [24] [25] [26] . The clinical spectrum and severity of illness appears similar to that expected for Enterobacteriaceae infections in this patient population. There is a paucity of information on the extent and mode of transmission of NDM-1-producing bacteria in the community and in healthcare settings. By analogy with the epidemiology of the bacterial host, indirect faecal-oral inter-human transmission is likely to play a major role, via contaminated hands, food or water, particularly in countries with limited access to adequate sanitary infrastructure. In India, the majority of NDM-1-producing Enterobacteriaceae were community-acquired [2, 7] . In the present survey, travel-associated cases who had had no contact with healthcare systems presumably acquired NDM-1 in the community [16, 24] .
Control interventions
Screening of colonisation with multidrug-resistant organisms upon admission to hospitals has been advocated in patients who have received healthcare in endemic countries or epidemic facilities [28] [29] [30] [31] .
Further interventions include preemptive isolation of these patients in single bedrooms and barrier precautions for the period while the screening results are pending, and continued for colonised patients [28] [29] [30] [31] . So far, evidence of secondary nosocomial transmission of bacteria with the NDM-1 enzyme in Europe is limited, possibly as the result of such proactive infection control measures. Evidence-based control measures should be identified for all carbapenemase-positive bacteria and implemented in patient care.
Public health response
Public health preparedness for the control of carbapenemase-producing Enterobacteriaceae, including those producing NDM-1 enzyme, is progressing across Europe as evidenced by our survey (Table 2) . Key components of current public health practices include (i) dissemination of national guidelines for microbiological laboratory detection, and (ii) recommendations for active surveillance and additional infection control precautions for patients who have received cross-border healthcare. Laboratory and epidemiological support should be readily available for the investigation of imported or indigenous cases and for the control of secondary transmission. Recent experiences with large epidemics of KPC and VIM carbapenemase-producing Enterobacteriaceae associated with significant mortality in the US, Greece and Israel, have highlighted the need for strengthening public health and the response capacity of healthcare systems, notably by dedicated national task forces and public health laboratory networks [28] [29] [30] . Member States could also consider providing information to their citizens seeking healthcare in foreign countries about the risk of acquiring NDM-1 and other extensively antibiotic-resistant bacterial pathogens.
EU-wide surveillance should be strengthened to enable monitoring of extensively antibiotic-resistant pathogens such as carbapenemase-producing Enterobacteriaceae. Linking national reference laboratories and public health institutes through antimicrobial resistance surveillance networks such as the EARS-Net, implementing national generic communicable diseases reporting and early warning systems to ensure rapid communication and a timely response, could be further studied as best practice to be shared among countries for effective containment of these extensively resistant pathogens. At the EU level, rapid information exchange by means of electronic communication platforms such as the Epidemic Intelligence System (EPIS) [32] or the Early Warning and Response System (EWRS) would result in an integrated European approach.
